BiotechTube
Home/Pipeline/UCB0107

UCB0107

Parkinson's Disease

Phase 1Active

Key Facts

Indication
Parkinson's Disease
Phase
Phase 1
Status
Active
Company
UCB

About UCB

UCB S.A. is a multinational biopharmaceutical company founded in 1928, originally as Union Chimique Belge. The company has evolved from a diversified chemical company into a focused biopharmaceutical leader with approximately 8,500 employees worldwide. UCB concentrates on patient solutions in neurology and immunology, with a strong portfolio of approved medicines including Keppra for epilepsy, Cimzia for inflammatory diseases, and Vimpat for seizure disorders.

View full company profile

Therapeutic Areas

NeurologyImmunologyEpilepsyParkinson's DiseaseMultiple SclerosisRheumatoid ArthritisPsoriasisInflammatory Diseases

Other Parkinson's Disease Drugs

DrugCompanyPhase
ABBV-951AbbViePhase 3
StalevoOrion CorporationApproved
Comtan/ComtessOrion CorporationApproved
CHRONOS-PD PlatformGrifolsResearch
GT-001 (Gene Therapy)Sumitomo PharmaPhase 1/2
CREXONT (Carbidopa/Levodopa)Amneal PharmaceuticalsApproved
BIIB122/DNL151Denali TherapeuticsPhase 3
ABBV-0805BioArctic ABPhase 1
BAN1202BioArctic ABPreclinical
ARV-102ArvinasPhase 1
AAV-GADMeiraGTxPreclinical/Phase 1
Not SpecifiedMinerva NeurosciencesClinical Stage